Answers are grounded in this paper and cite their sources.
Initial experience reveals complete obliteration in all patients treated for brain arteriovenous malformations, suggesting a promising role for extra-low viscosity agents.
Background and purpose This study presents our initial experience using iht Obtura, a novel nonadhesive liquid embolic agent with extra-low viscosity variants, in transvenous curative embolization of brain arteriovenous malformations (bAVMs). We assess the agent's performance and compare its advantages with other extra-low viscosity options currently available. Materials and methods Five patients (three females, two males; mean age, 33 years; range, 20–55 years) with ruptured bAVMs were treated using the transvenous retrograde pressure cooker technique (TVRPCT). Three patients underwent staged embolization for large bAVMs, with the final session performed using TVRPCT, while two patients with smaller bAVMs were treated in a single session. Results Complete obliteration was achieved in 100% of patients. The mean volume of iht Obtura used per transvenous session was 7.9 mL (range, 2–14 mL) ± 4.8. A combination of iht Obtura 15 and iht Obtura 12 was used in three cases, while iht Obtura 15 alone was used in two cases. Complete angiographic occlusion was sustained at six and 24 months follow-up. Clinical outcomes improved in three patients and remained unchanged in two (mRS = 0). Conclusions The TVRPCT with extra-low viscosity iht Obtura appears to be as safe and effective as other extra-low viscosity nonadhesive liquid embolic agents for curative treatment of bAVMs. The penetration, diffusion, and distribution of iht Obtura through the transvenous route were optimal, with no observed vascular rupture or extravasation.
No takes yet. Share an insight, caveat, or question.
Llíbre-Guerra et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: